{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:04:48Z","timestamp":1791266688442,"version":"4.1.0"},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,8,16]],"date-time":"2006-08-16T00:00:00Z","timestamp":1155686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Cryptosporidiosis in patients with acquired immune deficiency syndrome is a serious, life\u2010threatening disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>A large compassionate use clinical trial was conducted in the USA to make nitazoxanide available to patients with acquired immune deficiency syndrome\u2010related cryptosporidiosis and to collect data related to safety and effectiveness of the drug in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients at least 3\u2003years of age with acquired immune deficiency syndrome, diarrhoea (\u22654 stools\/day for &gt;2\u2003weeks) and <jats:italic>Cryptosporidium<\/jats:italic>\u2010positive stools received 500\u20131500\u2003mg of nitazoxanide twice daily. Patients were evaluated at weeks 1, 2, 4 and monthly thereafter for drug safety and effectiveness including the stool examinations, review of symptoms and patient diaries. Data analysis for clinical and parasitological response was intention\u2010to\u2010treat.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three hundred and sixty\u2010five patients were enrolled at 165 study centres throughout the USA. The duration of treatment ranged from 1 to 1528\u2003days (median 62\u2003days). Among the 357 patients included in the intent\u2010to\u2010treat analysis, 209 (59%) achieved a sustained clinical response while on treatment. Clinical responses were closely associated with <jats:italic>Cryptosporidium<\/jats:italic>\u2010negative stools (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001). No safety issues were identified at doses up to 3000\u2003mg\/day or for long durations of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Nitazoxanide can be considered useful therapy for treatment of with acquired immune deficiency syndrome\u2010related cryptosporidiosis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2006.03033.x","type":"journal-article","created":{"date-parts":[[2006,8,16]],"date-time":"2006-08-16T09:21:33Z","timestamp":1155720093000},"page":"887-894","source":"Crossref","is-referenced-by-count":68,"title":["Nitazoxanide in the treatment of acquired immune deficiency syndrome\u2010related cryptosporidiosis: results of the United States compassionate use program in 365 patients"],"prefix":"10.1111","volume":"24","author":[{"given":"J.\u2010F.","family":"ROSSIGNOL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,8,16]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.1.145-154.2002"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra013170"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199407213310304"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-006-0021-8"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.1959"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2877"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.1.57"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.14411\/fp.2003.003"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki456"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/321008"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2005.12.020"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11401-2"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(98)90804-5"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.03033.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.03033.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T06:52:01Z","timestamp":1697179921000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.03033.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,16]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1111\/j.1365-2036.2006.03033.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03033.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,16]]}}}